Jeito Capital II's €1B European Biopharma Fund: LPs Back EU Healthcare at Scale
Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.
Explore our latest articles on paris — covering venture capital deals, fund activity, startup fundraising strategy, and investor research relevant to this topic.
Whether you're a founder building an investor target list, an analyst tracking deal flow, or an operator researching market trends, the articles below provide practical, up-to-date venture capital intelligence.
Browse all paris articles below, or use our VC directory to research active investors by stage and sector.
Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.
VivaTech 2026 returns June 17–20 with 180,000+ attendees and 3,600+ investors — here's how founders and VCs should play it.
With €1.7B equity, $830M in debt, and a Paris datacenter plan, Mistral is turning 'European AI sovereignty' into a funded industrial strategy.
Parallel's Paris round highlights Europe's growing confidence in vertical AI agents for regulated industries like healthcare.
EGIDE's Paris seed round is a microcosm of France's push for sovereign counter-UAV systems and dual-use defense tech.
Escape's Series A highlights France's growing presence in AI security tooling — and the need for continuous API attack-surface monitoring.